Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
Clinical trial NCT04652700 · TERMINATED
Trial details
- NCT number
- NCT04652700
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-15
- Primary completion
- 2023-08-04
- Enrollment
- 494
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.